Composition containing magnesium salt and probiotics and application

Abstract

The invention discloses a composition containing magnesium salt and probiotics and application of the composition. The invention belongs to the technical field of dietary nutrition supplements. Wherein the composition further comprises a metagen component and a polysaccharide component, and the composition can be used for relieving flatulence, stomachache, diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease and other intestinal tracts.

Description

Technical Field

[0001] The present invention belongs to the field of dietary nutritional supplements and relates to a composition containing magnesium salts and probiotics. The composition further contains postbiotics and polysaccharides, and the use of the composition in relieving intestinal problems such as flatulence, abdominal pain, diarrhea, constipation, irritable bowel syndrome, and inflammatory bowel disease. Background Art

[0002] Constipation is a decrease in the frequency of bowel movements or difficulty in defecation, with hard stools or a feeling of incomplete evacuation of the rectum after defecation, which affects people's quality of life. Combining exercise, a high-fiber diet, and adequate fluid intake is the best way to prevent constipation. In addition, taking some dietary nutritional supplements plays an effective role in relieving constipation.

[0003] Osmotic agents promote the entry of a large amount of water into the large intestine, softening and loosening the stools. Excessive fluid stretches the large intestine wall and stimulates contractions. Some salts, including salts containing magnesium ions and phosphate ions, such as magnesium hydroxide, magnesium sulfate, magnesium phosphate, etc., have the effect of clearing the intestines and removing endotoxins from the intestines by promoting osmosis and stimulating intestinal motility.

[0004] In addition, the intestinal flora is the core part of the intestinal microecology, and probiotics play a role in maintaining intestinal homeostasis and treating intestinal diseases. Intestinal probiotics attach to the intestinal wall through adhesion, further colonize, and then form a microbial film on the surface of the adhesion membrane to prevent the invasion of foreign bacteria and protect the health of the intestinal mucosa.

[0005] Providing an effective dietary nutritional supplement whose composition can be used to relieve flatulence, abdominal pain, diarrhea, constipation, irritable bowel syndrome, and inflammatory bowel disease is a technical problem to be solved. Summary of the Invention

[0006] The purpose of the present invention is to provide a composition containing magnesium salts and probiotics in view of the deficiencies of the prior art.

[0007] Furthermore, the magnesium salt is one or a combination of several of magnesium hydroxide, magnesium sulfate, magnesium phosphate, magnesium oxide, magnesium citrate, magnesium carbonate, magnesium chloride, magnesium threonate, and magnesium gluconate.

[0008] The content of the magnesium salt in the present invention is not less than 250 mg per portion; preferably, not less than 350 mg per portion; more preferably, not less than 450 mg per portion.

[0009] Furthermore, the probiotic is one or a combination of several of Lactobacillus, Lactobacillus casei, Bifidobacterium, Lactobacillus acidophilus, Lactobacillus acidophilus, Bacillus licheniformis, Streptococcus faecalis, Bacillus subtilis, Clostridium butyricum, Clostridium butyricum, and Akkermansia muciniphila.

[0010] The bacterial count of the probiotics in the present invention is not less than 1 billion per portion of the composition, preferably not less than 5 billion per portion; more preferably not less than 10 billion per portion.

[0011] Furthermore, the composition includes postbiotics.

[0012] In the present invention, the form of the postbiotics can be paste form, suspension form, emulsion form, powder form, granule form, and preferably powder form.

[0013] The postbiotics in the present invention further include one or several combinations of Lactobacillus casei, Lactiplantibacillus plantarum, Bifidobacterium breve, Streptococcus thermophilus, Bifidobacterium bifidum, Lactobacillus rhamnosus, r-aminobutyric acid, short-chain fatty acids, and tryptophan.

[0014] The content of the postbiotics in the present invention is not less than 1 billion per portion of the composition, preferably not less than 5 billion per portion; more preferably not less than 10 billion per portion.

[0015] The probiotics and postbiotics in the present invention are not less than 1 billion per portion of the composition, preferably not less than 5 billion per portion; more preferably not less than 10 billion per portion.

[0016] Furthermore, the composition includes polysaccharides.

[0017] The polysaccharides in the present invention are extracts from okra, common mallow, hollyhock, winter mallow, dandelion, scutellaria baicalensis, chrysanthemum, agaricus blazei, quinoa, jujube, apple, nostoc commune, ginseng, purple sweet potato, dictyophora indusiata, flammulina velutipes, wolfberry, cordyceps militaris.

[0018] The content of the polysaccharides in the present invention is not less than 1 mg per portion; preferably not less than 3 mg per portion; more preferably not less than 10 mg per portion.

[0019] Polysaccharides are widely present in the tissue cells of plants, animals, and microorganisms. Polysaccharide extracts can lubricate the intestinal mucosa and repair intestinal epithelial cells; they can also regulate the richness of the intestinal flora, increase the level of beneficial bacteria, and reduce the pH value of the intestine.

[0020] Polysaccharide extracts can be obtained by water extraction method, microwave extraction method, enzymatic extraction method, and ultrasonic extraction method.

[0021] Furthermore, the composition described in the present invention does not include stimulant laxatives. The stimulant laxatives include one or several combinations of phenolphthalein, bisacodyl, and anthraquinones.

[0022] The stimulant laxatives in the present invention include one or several combinations of aloe, senna leaf, rhubarb, bamboo leaves, senna occidentalis leaf, cassia seed, castor oil, and phenolphthalein.

[0023] Stimulating laxatives act on the enteric nervous system. Long-term use is likely to cause drug dependence, darken the intestines, and increase the risk of colon cancer.

[0024] The products of the composition described in the present invention can be in various dosage forms, including but not limited to common dosage forms of drugs, such as powders, suppositories, gels, oral liquids, liquid preparations, capsules, soft capsules, powders, granules, tablets, and can also be common dosage forms of health foods and dietary supplements, such as tablets, hard capsules, soft capsules, beverages, solid beverages, soft drinks, soluble beans, freeze-dried powders, milk beans, chocolates, soft candies with fillings, chocolate with fillings, tea beverages, cold-brewed coffee, and gummy candies.

[0025] The various dosage forms of the products for treating and / or improving intestinal health described in the present invention can be prepared according to the conventional production and preparation methods of drugs, health foods, ordinary foods, daily chemicals, feeds, additives, etc. One or more carriers in this component are mixed and then made into the required dosage form.

[0026] As active microorganisms, probiotics maintain the health of the body's gastrointestinal tract, improve the intestinal flora, and form a healthy gastrointestinal ecosystem through mechanisms such as promoting the proliferation of beneficial bacteria, enhancing the intestinal mucosal barrier, reducing intestinal inflammation, inhibiting the activity of pathogenic bacteria, and regulating cell proliferation and apoptosis reactions.

[0027] As inanimate microorganisms, postbiotics mainly consist of inactivated bacterial cells, bacterial lysates, cell wall components, and metabolites, etc. The beneficial metabolites of probiotics, such as γ-aminobutyric acid, short-chain fatty acids, tryptophan, etc., are also components of postbiotics, and they maintain the integrity of the intestinal barrier by regulating the intestinal flora.

[0028] The present invention provides the use of a magnesium salt and probiotic composition in the preparation of a composition for relieving intestinal problems such as flatulence, abdominal pain, diarrhea, constipation, irritable bowel syndrome, and inflammatory bowel disease.

[0029] Term Explanation

[0030] As used herein, "postbiotics" is a general term for the beneficial bacterial components after processing probiotics, including bacterial cells and metabolites.

[0031] As used herein, "polysaccharide" is composed of multiple monosaccharide molecules linked by glycosidic bonds and is a class of carbohydrates with complex and large molecular structures.

[0032] As used herein, "extract" is a product obtained by the process of physical and chemical extraction and separation of raw materials to obtain and concentrate them directionally. Detailed Embodiments

[0033] For the convenience of those skilled in the art, the present invention will be further described below in conjunction with embodiments. The content mentioned in the embodiments does not limit the present invention.

[0034] Example 1

[0035] A composition comprising magnesium oxide and Lactobacillus casei, wherein the magnesium content is 350 mg per portion, Lactobacillus casei is an inactivated bacterium, and the cell count is 1 billion cells per portion.

[0036] Example 2

[0037] A composition comprising magnesium hydroxide and Lactiplantibacillus plantarum, wherein the magnesium is 350 mg, Lactiplantibacillus plantarum is an inactivated bacterium, and the cell count is 1 billion cells per portion.

[0038] Example 3

[0039] A composition comprising magnesium sulfate and Limosilactobacillus salivarius, wherein the magnesium is 350 mg, and the cell count of Limosilactobacillus salivarius is 1 billion CFU per portion.

[0040] Example 4

[0041] A composition comprising magnesium phosphate and Lactobacillus acidophilus, wherein the magnesium is 350 mg, and the cell count of Lactobacillus acidophilus is 1 billion CFU per portion.

[0042] Example 5

[0043] A composition comprising magnesium citrate and Bifidobacterium breve, wherein the magnesium is 350 mg, and the cell count of Bifidobacterium breve is 1 billion CFU per portion.

[0044] Example 6

[0045] A composition comprising magnesium carbonate and Streptococcus thermophilus, wherein the magnesium is 350 mg, and the cell count of Streptococcus thermophilus is 1 billion CFU per portion.

[0046] Example 7

[0047] A composition comprising magnesium chloride and Lactobacillus casei subsp. casei, wherein the magnesium is 250 mg, Lactobacillus casei subsp. casei is an inactivated bacterium, and the cell count is 5 billion cells per portion.

[0048] Example 8

[0049] A composition comprising magnesium threonate and Lactobacillus rhamnosus, wherein the magnesium is 350 mg, and the cell count of Lactobacillus rhamnosus is 1 billion CFU per portion.

[0050] Example 9

[0051] A composition comprising magnesium gluconate and Bifidobacterium bifidum, wherein the magnesium content is 350 mg and the amount of Bifidobacterium bifidum is 1 billion CFU per portion.

[0052] Example 10

[0053] A composition comprising magnesium oxide and Lactobacillus, wherein the magnesium content is 250 mg and the amount of Lactobacillus is 5 billion CFU per portion.

[0054] Example 11

[0055] A composition comprising magnesium oxide and Bifidobacterium, wherein the magnesium content is 250 mg and the amount of Bifidobacterium is 5 billion CFU per portion.

[0056] Example 12

[0057] A composition comprising magnesium oxide and Clostridium butyricum, wherein the magnesium content is 250 mg and the amount of Clostridium butyricum is 5 billion CFU per portion.

[0058] Example 13

[0059] A composition comprising magnesium oxide and Akkermansia, wherein the magnesium content is 250 mg and the amount of Akkermansia is 5 billion CFU per portion.

[0060] Example 14

[0061] A composition comprising magnesium oxide, Lactobacillus casei, and okra extract, wherein the magnesium content is 250 mg and the amount of Lactobacillus casei is 5 billion cells per portion.

[0062] Example 15

[0063] A composition comprising magnesium oxide, Lactobacillus casei, okra extract, and licorice extract, wherein the magnesium content is 350 mg and the amount of Lactobacillus casei is 5 billion cells per portion.

[0064] Example 16

[0065] A method for preparing a composition, the composition comprising magnesium oxide and inactivated Lactobacillus casei, wherein the magnesium content is 450 mg and the amount of Lactobacillus casei is 5 billion cells per portion. Magnesium oxide, Lactobacillus casei, and excipients are separately pulverized, sieved, further mixed, tableted, and coated.

[0066] Example 17

[0067] A method for preparing a composition, the composition comprising magnesium oxide and Akkermansia, wherein the magnesium content is 450 mg and the amount of Akkermansia is 5 billion CFU. Magnesium oxide, Akkermansia, and excipients are separately pulverized, sieved, further mixed to obtain a uniformly mixed material before capsule filling, and the capsule shell is filled to obtain capsules.

[0068] Example 18

[0069] Mouse experiment, experimental method: Loperamide was administered to mice at a dose of 8 mg / (kg·d) to induce constipation in mice; 0.5 h after the last administration, the mice were given gavage treatment according to the above-mentioned example at a gavage dose of 250 mg / (kg·d), and the first defecation time of the mice, the fecal weight at 24 h, and the fecal water content were recorded.

[0070] First defecation time: The time elapsed from the end of gavage to the first defecation;

[0071] Total fecal weight: The total fecal weight of each mouse defecated within 24 h after gavage (calculated as the average value of the mice in the group)

[0072] Fecal water content % = (fecal wet weight - fecal dry weight) / fecal wet weight * 100%. The results are shown in the following table:

[0073] Table 1 Animal experiment on the composition for relieving constipation

[0074]

[0075] As can be seen from Table 1, after taking the composition containing magnesium salt and probiotics, the defecation time was significantly improved, and to a certain extent, the fecal volume was increased, making the feces softer, and the fecal water content of constipated mice was normalized.

[0076] Those skilled in the art of the present technology can understand that, unless otherwise defined, all terms (including technical terms and scientific terms) used herein have the same meaning as the general understanding of those of ordinary skill in the art to which the present invention belongs. It should also be understood that terms such as those defined in a general dictionary should be understood to have a meaning consistent with the meaning in the context of the prior art, and will not be interpreted in an idealized or overly formal sense unless specifically defined as here.

[0077] It should be understood that the detailed description of the technical solutions of the present invention by means of the preferred embodiments above is illustrative rather than restrictive. Those of ordinary skill in the art can modify the technical solutions recorded in each embodiment on the basis of reading the specification of the present invention, or perform equivalent substitution on some of the technical features; and these modifications or substitutions do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of each embodiment of the present invention.

Claims

1. A composition, characterized in that, Contains magnesium salts and probiotics.

2. The composition according to claim 1, wherein The magnesium salt is one or a combination of magnesium hydroxide, magnesium sulfate, magnesium phosphate, magnesium oxide, magnesium citrate, magnesium carbonate, magnesium chloride, magnesium threonate, and magnesium gluconate.

3. The composition according to claim 1 or 2, wherein the magnesium content in the magnesium salt is not less than 250 mg per portion.

4. The composition according to claim 1, characterized in that, The probiotics are one or a combination of Lactobacillus, Lactobacillus casei, Bifidobacterium, Lactobacillus acidophilus, Lactobacillus acidophilus, Bacillus licheniformis, Streptococcus faecalis, Bacillus subtilis, Butyricicoccus pullicaecorum, Clostridium butyricum, Akkermansia muciniphila.

5. The composition according to claim 1 or 4, wherein the viable count of the probiotics is not less than 1 billion per portion of the composition.

6. The composition according to claim 1, further comprising postbiotics.

7. The composition according to claim 6, wherein the postbiotics further comprise one or a combination of Lactobacillus casei, Lactiplantibacillus plantarum, Bifidobacterium breve, Streptococcus thermophilus, Bifidobacterium bifidum, Lactobacillus rhamnosus, r-aminobutyric acid, short-chain fatty acids, and tryptophan.

8. The composition according to claim 6, wherein the content of the postbiotics is not less than 1 billion per portion of the composition.

9. The composition according to claim 6, wherein the total viable count of the probiotics and postbiotics is not less than 1 billion per portion of the composition.

10. The composition according to claim 1, further comprising polysaccharides.

11. The composition according to claim 10, wherein the polysaccharides are extracts from okra, Malva sylvestris, Althaea rosea, Malva verticillata, Taraxacum mongolicum, Scutellaria baicalensis, Chrysanthemum morifolium, Agaricus blazei, quinoa, jujube, apple, Nostoc commune, Panax ginseng, purple sweet potato, Dictyophora indusiata, Flammulina velutipes, Lycium barbarum, Cordyceps militaris.

12. The composition according to claim 10, wherein the content of the polysaccharides is 0.001 - 0.1 g per portion.

13. The composition according to claim 1 does not include stimulant laxatives.

14. The composition according to claim 13, wherein the stimulant laxatives are one or a combination of phenolphthalein, bisacodyl, and anthraquinones.

15. The pharmaceutical composition according to claim 13, wherein the stimulant laxatives are one or a combination of aloe vera, senna leaves, rhubarb, bamboo leaves, cassia angustifolia, castor oil, and phenolphthalein.

16. The use of the composition according to any one of claims 1 to 15 in relieving intestinal problems such as flatulence, abdominal pain, diarrhea, constipation, irritable bowel syndrome, and inflammatory bowel disease.

17. The composition according to any one of claims 1 to 15 is prepared into soft capsules, liquid preparations, granules, powders, capsules, and tablets.

Images